TEX CORE

A first in class drug platform, TEX Core conjugates with oncology therapies to create novel compounds that are delivered directly to tumor cells with minimal side effects.

star

A NEW ERA FOR CANCER THERAPY

TEX Core-developed compounds are designed to be tumor localizing, well-tolerated, MRI-detectable and efficacious in multiple solid tumors, including cancer cells that fail to respond to current therapies.

OncoTEX Inc. is progressing the TEX Core platform development, in collaboration with The University of Texas at Austin to develop and commercialize a pipeline of oncology compounds with optimal efficacy for treating a range of different cancers.

OXALITEX TRIPLE MECHANISM OF ACTION

1

Localizes to solid tumors with minimal side effects.

2

Increases uptake of platinum into drug-resistant cells compared with other platinum-based drugs.

3

Reactivates the P53 gene to override inherent platinum resistance.

PIPELINE

OncoTEX Inc. has a robust pipeline of seven drug candidates at different stages of development for multiple solid tumor indications. The first clinical conjugate for the TEX Core platform will be based on the OxaliTEX compound. The lead indication for the OxaliTEX development program is platinum resistant ovarian cancer – the number one cause of gynaecological cancer deaths worldwide. The future applications include Lung cancer, Colorectal cancer, and Glioblastoma multiforme (brain cancer). Other compounds in the pipeline for the treatment of additional cancers include: MangaTEX, AuraTEX, ParpTEX and GemTEX.

Platinum+TEX Core(Chemotherapy) Platinum resistant ovarian, metastatic ovarian, WT KRAS colorectal, non-small-cell lung carcinoma, glioblastoma multiforme (MGMT positive cancers) PARPi Combination Taxane Combination Manganese +TEX Core (Photothermal Therapy) Triple negative breast, metastatic breast, BRCA mutant breast cancers MangaTEX OxaliTEX Prostate, fallopian tube cancers ParpTEX PARPi+TEX Core(Targeted Therapy) Large-cell lung carcinoma, pancreatic, advanced breast, recurrent platinum sensitive ovarian cancers GemTEX DNA Replication Inhibitors+TEX Core(Chemotherapy) Early-stage breast, small-cell lung carcinoma , gastric cancers DoxTEX Anthracyclines +TEX Core (Chemotherapy) Breast cancer, lung cancer, pancreatic cancer and lung cancer AuraTEX Immunotherapies+TEX Core(Immunotherapy) Taxol resistant breast, bladder, prostate cancers TaxTEX Taxanes+TEX Core(Chemotherapy) PROGRAM DRUG CANDIDATE PRE-CLINICAL DEVELOPMENT PROOF OF CONCEPT PROOF OF CONCEPT PROOF OF CONCEPT INDICATION DISCOVERY i PROOF OF CONCEPT i PRE-CLINICAL DEVELOPMENT i PHASE II i PHASE I i DISCOVERY DISCOVERY DISCOVERY DISCOVERY

Timeline

2021

OxaliTEX patent issued in Singapore, Australia, Israel

MangaTEX PCT application filed

OncoTEX attended and presented at the AACR national conference

OxaliTEX co-inventor, Dr Jonathan Arambula appointed as OncoTEX CEO

AuraTEX platform technology licensed to OncoTEX from University of Texas at Austin

2020

OncoTEX Team publishes landmark OxaliTEX preclinical trial findings in Proceedings of the National Academy of Sciences (PNAS)1

OxaliTEX as a potential antitumor agent1

OxaliTEX Chemistry paper published discussing field

OxaliTEX patent issued in Mexico

MangaTEX JACS paper published15

MangaTEX; a paramagnetic photoacoustic contrast agent15

MangaTEX licensed to OncoTEX

AuraTEX JACS paper published16

Rationally designed AuraTEX; An immunogenic cell death inducer16

AuraTEX PCT application filed

2019

OxaliTEX patent issued in US

The iQ Group Global Ltd. company, OncoTEX Inc., acquires the exclusive license to the TEX Core technology & OxaliTEX

Co-inventor, Dr Jonathan Arambula, joins The iQ Group Global as VP, Research, OncoTEX Inc.

Co-inventor, Prof Jonathan Sessler, joins the board of OncoTEX Inc. & the Scientific Advisory Board (SAB), OxaliTEX patent issued in US

2018

OncoTEX Inc. is incorporated in anticipation of the acquisition of TEX Core technology & OxaliTEX

2016

Publication: Discovery of texaphyrin ability to activate Pt(IV) pro-drug20

2015

OxaliTEX patent application published (PCT/US2015/035229)

2014

OxaliTEX (current Pt(IV) form) developed

Research grant from Cancer Prevention and Research Institute of Texas (CPRIT) awarded to University of Texas at Austin

Texaphyrin-oxaliplatin conjugate patent filedTexaphyrin-oxaliplatin conjugate patent filed

2012

Publication: Further evidence of ability to overcome drug resistance with texaphyrin-oxaliplatin(II) conjugate

2011

Publication: Texaphyrin-platinum chemo conjugation demonstrates ability to overcome resistance

Research grant from Cancer Prevention and Research Institute of Texas (CPRIT) awarded to University of Texas at Austin

2009

Publication: Texaphyrin-platinum chemo conjugation efficacy in resistant ovarian cancer cells

Collaboration between University of Texas and MD Anderson Cancer Center

Zahid Siddik joins drug discovery team

Research grants from American Cancer Society and National Institute of Health awarded to University of Texas at Austin

2008

Dr. Jonathan Arambula joins the drug discovery team at The University of Texas at Austin

1994

Texaphyrin found to localize to tumors & able to be used as “delivery vehicle” for cancer therapeutics

Mid-late 1980’s

Publication: Prof Jonathan Sessler publishes on the discovery of Texaphyrin19